Compare HLP & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLP | QTTB |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.2M | 265.2M |
| IPO Year | 2021 | 2018 |
| Metric | HLP | QTTB |
|---|---|---|
| Price | $3.85 | $8.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 238.7K | ★ 519.2K |
| Earning Date | 11-17-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $1.91 |
| 52 Week High | $4.69 | $23.57 |
| Indicator | HLP | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 81.55 | 46.44 |
| Support Level | $0.98 | $7.45 |
| Resistance Level | N/A | $9.16 |
| Average True Range (ATR) | 0.33 | 0.50 |
| MACD | 0.06 | 0.21 |
| Stochastic Oscillator | 64.13 | 71.54 |
Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).